Background The biological processes associated with postacute sequelae of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown. Methods …

Importance The evidence for benefit of convalescent plasma for critically ill patients with
COVID-19 is inconclusive. Objective To determine whether convalescent plasma would …

Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

SARS-CoV-2 infection poses a major threat to the lungs and multiple other organs,
occasionally causing death. Until effective vaccines are developed to curb the pandemic, it …

Objectives: Screen individuals based on exposure and symptom criteria to identify potential
COVID-19 cases. Identify the clinical features and radiological findings expected in patients …

Cytokine storm syndrome (CSS) has generally been described as a collection of clinical
manifestations resulting from an overactivated immune system. Cytokine storms (CSs) are …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …

Background Elevated proinflammatory cytokines are associated with greater COVID-19
severity. We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor …

Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …